Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr;31(7):806-14.
doi: 10.1093/eurheartj/ehq025. Epub 2010 Feb 19.

Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria

Frank I Marcus  1 , William J McKenna, Duane Sherrill, Cristina Basso, Barbara Bauce, David A Bluemke, Hugh Calkins, Domenico Corrado, Moniek G P J Cox, James P Daubert, Guy Fontaine, Kathleen Gear, Richard Hauer, Andrea Nava, Michael H Picard, Nikos Protonotarios, Jeffrey E Saffitz, Danita M Yoerger Sanborn, Jonathan S Steinberg, Harikrishna Tandri, Gaetano Thiene, Jeffrey A Towbin, Adalena Tsatsopoulou, Thomas Wichter, Wojciech Zareba
Affiliations

Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria

Frank I Marcus et al. Eur Heart J. 2010 Apr.

Abstract

Background: In 1994, an International Task Force proposed criteria for the clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) that facilitated recognition and interpretation of the frequently nonspecific clinical features of ARVC/D. This enabled confirmatory clinical diagnosis in index cases through exclusion of phenocopies and provided a standard on which clinical research and genetic studies could be based. Structural, histological, electrocardiographic, arrhythmic, and familial features of the disease were incorporated into the criteria, subdivided into major and minor categories according to the specificity of their association with ARVC/D. At that time, clinical experience with ARVC/D was dominated by symptomatic index cases and sudden cardiac death victims-the overt or severe end of the disease spectrum. Consequently, the 1994 criteria were highly specific but lacked sensitivity for early and familial disease.

Methods and results: Revision of the diagnostic criteria provides guidance on the role of emerging diagnostic modalities and advances in the genetics of ARVC/D. The criteria have been modified to incorporate new knowledge and technology to improve diagnostic sensitivity, but with the important requisite of maintaining diagnostic specificity. The approach of classifying structural, histological, electrocardiographic, arrhythmic, and genetic features of the disease as major and minor criteria has been maintained. In this modification of the Task Force criteria, quantitative criteria are proposed and abnormalities are defined on the basis of comparison with normal subject data.

Conclusions: The present modifications of the Task Force Criteria represent a working framework to improve the diagnosis and management of this condition. Clinical Trial Registration clinicaltrials.gov Identifier: NCT00024505.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The cardiac desmosome and proposed roles of the desmosome in (A) supporting structural stability through cell–cell adhesion, (B) regulating transcription of genes involved in adipogenesis and apoptosis, and maintaining proper electrical conductivity through regulation of (C) gap junctions and (D) calcium homeostasis. Dsc2 indicates desmocollin-2; Dsg2, desmoglein-2; Dsp, desmoplakin; Pkg, plakoglobin; Pkp2, plakophilin-2; and PM, plasma membrane. Reprinted by permission from Macmillan Publishers Ltd: Nat Clin Pract Cardiovasc Med11, © 2008.
Figure 2
Figure 2
Endomyocardial biopsy findings in a proband affected by a diffuse form of ARVC/D. All 3 biopsy samples are from different regions of the RV free wall. There is extensive fibrofatty tissue replacement with myocardial atrophy, which is a major criterion (i.e. residual myocytes <60% by morphometric analysis or <50% if estimated). Contributed by C. Basso, Padua, Italy.
Figure 3
Figure 3
ECG from proband with T-wave inversion in V1 through V4 and prolongation of the terminal activation duration ≥55 ms measured from the nadir of the S wave to the end of the QRS complex in V1. Contributed by M.G.P.J. Cox, Utrecht, The Netherlands.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Basso C, Corrado D, Marcus FI, Nava A, Thiene G. Arrhythmogenic right ventricular cardiomyopathy. Lancet. 2009;373:1289–1300. - PubMed
    1. Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C, Grosgogeat Y. Right ventricular dysplasia: a report of 24 adult cases. Circulation. 1982;65:384–398. - PubMed
    1. Corrado D, Basso C, Thiene G, McKenna WJ, Davies MJ, Fontaliran F, Nava A, Silvestri F, Blomstrom-Lunquist C, Wlodarska EK, Fontaine G, Camerini F. Spectrum of clinicopathologic manifestation of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. 1997;6:1512–1520. - PubMed
    1. Norman M, Simpson N, Mogensen J, Shaw A, Hughes S, Syrris P, Sen-Chowdhry S, Rowland E, Crosby A, McKenna WJ. Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation. 2005;112:636–642. - PubMed
    1. Basso C, Thiene G. Autopsy and endomyocardial biopsy findings. In: Marcus FI, Nava A, Thiene G, editors. Milan, Italy: Springer Verlag; 2007. pp. 29–44. Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia.

Publication types

MeSH terms

Associated data